Ingalls & Snyder LLC’s Genmab GMAB Stock Holding History

Ingalls & Snyder LLC’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.96M	Sell	72,891 -214	-0.3%	-$6.41K	0.07%	156
2025 Q4	$2.25M	Sell	73,105 -34,169	-32%	-$1.07M	0.08%	152
2025 Q3	$3.29M	Sell	107,274 -12,210	-10%	-$298K	0.11%	122
2025 Q2	$2.47M	Sell	119,484 -29,831	-20%	-$612K	0.09%	144
2025 Q1	$2.92M	Buy	149,315 +13,256	+10%	+$278K	0.1%	121
2024 Q4	$2.84M	Sell	136,059 -82,424	-38%	-$1.81M	0.11%	121
2024 Q3	$5.33M	Sell	218,483 -11,217	-5%	-$300K	0.21%	83
2024 Q2	$5.77M	Buy	229,700 +52,117	+29%	+$1.48M	0.25%	73
2024 Q1	$5.31M	Buy	+177,583	New	+$5.22M	0.23%	72

Other funds holding GMAB

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Ingalls & Snyder LLC's GMAB Position: Q1 2026 in Review

Ingalls & Snyder LLC reduced its Genmab (GMAB) stake by 0.29% in Q1 2026, selling an estimated $6.41K and leaving 72,891 shares worth $1.96M. The position accounts for 0.07% of the portfolio, ranked #156.

Ingalls & Snyder LLC first reported a position in GMAB in Q1 2024 and has held it in 9 quarters since. The position peaked at $5.77M in Q2 2024. 272 funds tracked by Wall St. Rank hold GMAB as of Q1 2026.

Ingalls & Snyder LLC held 72,891 shares of Genmab worth $1.96M as of Q1 2026.
Ingalls & Snyder LLC sold 214 Genmab shares in Q1 2026, an estimated $6.41K.
Genmab made up 0.07% of Ingalls & Snyder LLC's portfolio in Q1 2026, its #156 holding.
Ingalls & Snyder LLC first reported a position in Genmab in Q1 2024 and has held it in 9 quarters since.
Ingalls & Snyder LLC's Genmab position peaked at $5.77M in Q2 2024.
272 funds tracked by Wall St. Rank held Genmab as of Q1 2026.

Based on Ingalls & Snyder LLC's 13F filing for Q1 2026, filed 13 May 2026.